Tema Etfs LLC Purchases 15,757 Shares of Medtronic PLC $MDT

Tema Etfs LLC increased its position in shares of Medtronic PLC (NYSE:MDT) by 76.6% in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,325 shares of the medical technology company’s stock after purchasing an additional 15,757 shares during the quarter. Tema Etfs LLC’s holdings in Medtronic were worth $3,460,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in MDT. Norges Bank acquired a new stake in shares of Medtronic during the second quarter worth approximately $1,432,698,000. Vanguard Group Inc. grew its position in Medtronic by 1.5% during the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after acquiring an additional 1,895,165 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in Medtronic by 332.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock valued at $130,300,000 after purchasing an additional 1,148,803 shares in the last quarter. Perkins Coie Trust Co raised its position in Medtronic by 2,952.2% in the 2nd quarter. Perkins Coie Trust Co now owns 1,155,425 shares of the medical technology company’s stock valued at $100,718,000 after purchasing an additional 1,117,570 shares during the last quarter. Finally, Laurel Wealth Advisors LLC raised its position in Medtronic by 8,779.8% in the 2nd quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after purchasing an additional 1,057,618 shares during the last quarter. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic Price Performance

MDT stock opened at $97.54 on Monday. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57. The stock has a market cap of $125.04 billion, a PE ratio of 26.29, a price-to-earnings-growth ratio of 2.57 and a beta of 0.71. Medtronic PLC has a 1 year low of $79.55 and a 1 year high of $106.33. The stock has a 50-day moving average price of $98.31 and a two-hundred day moving average price of $94.57.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The business had revenue of $8.96 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter last year, the firm earned $1.26 EPS. Medtronic’s revenue for the quarter was up 6.6% compared to the same quarter last year. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Equities analysts forecast that Medtronic PLC will post 5.46 EPS for the current fiscal year.

Medtronic Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, January 16th. Stockholders of record on Friday, December 26th will be given a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, December 26th. Medtronic’s payout ratio is currently 76.55%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on MDT. Stifel Nicolaus raised their target price on Medtronic from $90.00 to $105.00 and gave the company a “hold” rating in a research note on Thursday, October 9th. Sanford C. Bernstein increased their price objective on shares of Medtronic from $111.00 to $112.00 and gave the stock an “outperform” rating in a report on Friday. Piper Sandler reaffirmed a “neutral” rating on shares of Medtronic in a research note on Monday, January 5th. Robert W. Baird set a $103.00 target price on shares of Medtronic in a research report on Tuesday, December 16th. Finally, Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and eleven have assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).